Literature DB >> 488633

Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria.

T Fedorowski, G Salen, G S Tint, E Mosbach.   

Abstract

Feces from normal subjects and patients with cerebrotendinous xanthomatosis were incubated anaerobically with labeled chenodeoxycholic acid and ursodeoxycholine acid for known periods, and the bile acids formed were analyzed by TLC and scintillation counting. In the normal subjects, 80% of the chenodeoxycholic acid and 41% of the ursodeoxycholic acid were 7-dehydroxylated to lithocholic acid during 2 hr of incubation. In contrast, the fecal flora of the CTX patients transformed only 5% of chenodeoxycholic acid and less than 1% of ursodeoxycholic acid to lithocholic acid during the same time period. In several subjects (normals and CTX), the intestinal flora converted chenodeoxycholic acid to ursodeoxycholic acid without the accumulation of the hypothetical intermediate 7-ketolithocholic acid (3 alpha-hydroxy-7-keto-5 beta-cholanoic acid). These results indicate that the fecal bacterial flora is capable of 7-dehydroxylating chenodeoxycholic acid and ursodeoxycholic acid to yield lithocholic acid. Apparently the enzymes involved are relatively stereospecific since the 7 beta-hydroxy group of ursodeoxycholic acid was removed more slowly than the 7 alpha-hydroxy group of chenodeoxycholic acid.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 488633

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  29 in total

Review 1.  Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment.

Authors:  Karolina E Zaborska; Bethany P Cummings
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

Review 2.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

3.  In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.

Authors:  G Rudolph; D N Gotthardt; P Kloeters-Plachky; H Kulaksiz; P Schirmacher; A Stiehl
Journal:  Dig Dis Sci       Date:  2011-06-09       Impact factor: 3.199

4.  Rapidly directional biotransformation of tauroursodeoxycholic acid through engineered Escherichia coli.

Authors:  Jie Shi; Jie Wang; Lu Yu; Li Yang; Shujuan Zhao; Zhengtao Wang
Journal:  J Ind Microbiol Biotechnol       Date:  2017-03-22       Impact factor: 3.346

5.  A study on the mechanism of the epimerization at C-3 of chenodeoxycholic acid by Clostridium perfringens.

Authors:  F Aragozzini; E Canzi; A Ferrari; E Maconi; A Sidjimov
Journal:  Biochem J       Date:  1985-09-01       Impact factor: 3.857

6.  Hepatic and extrahepatic glucuronidation of bile acids in man. Characterization of bile acid uridine 5'-diphosphate-glucuronosyltransferase in hepatic, renal, and intestinal microsomes.

Authors:  S Matern; H Matern; E H Farthmann; W Gerok
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

7.  Characterization of NADP-dependent 7 beta-hydroxysteroid dehydrogenases from Peptostreptococcus productus and Eubacterium aerofaciens.

Authors:  S Hirano; N Masuda
Journal:  Appl Environ Microbiol       Date:  1982-05       Impact factor: 4.792

8.  Curcumin induces human cathelicidin antimicrobial peptide gene expression through a vitamin D receptor-independent pathway.

Authors:  Chunxiao Guo; Elena Rosoha; Malcolm B Lowry; Niels Borregaard; Adrian F Gombart
Journal:  J Nutr Biochem       Date:  2012-07-25       Impact factor: 6.048

9.  Retrospective comparison of 'Cheno' and 'Urso' in the medical treatment of gallstones.

Authors:  T J Meredith; G V Williams; P N Maton; G M Murphy; H M Saxton; R H Dowling
Journal:  Gut       Date:  1982-05       Impact factor: 23.059

10.  The bile acid composition of gastric contents from neonates with high intestinal obstruction.

Authors:  P T Clayton; D P Muller; A M Lawson
Journal:  Biochem J       Date:  1982-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.